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First use of intravenous artesunate in Liberia and eﬀ ect on 
patient mortality relative to artemeter and quinine: 
a cross-sectional study
Wilson Wang, Augustine Koryon, Bernice Dahn
Abstract
Background Intravenous artesunate reduces mortality by 35% relative to intravenous quinine. In 2010, WHO changed 
guidelines favouring intravenous artesunate, yet wide-scale adoption lags. In April, 2012, the Clinton Foundation with 
the Liberian Health Ministry brought intravenous artesunate into Liberia’s busiest paediatric centres, Redemption 
and JDJ. The Foundation reached out to the International Rescue Committee, a non-governmental organisation that 
supported the hospitals, to implement the change.
Methods We created a JDJ decision support instrument to guide and document proper intravenous artesunate 
administration. 4 months later, in July–October, 2012, we determined the proportion of children aged 1–16 years who 
were admitted for malaria with a positive rapid diagnostic test or malaria smear, the proportion who received 
intravenous artesunate, and the proportion who died. We compared these ﬁ ndings with the same period 1 year earlier 
when artesunate was not available.
Findings From July to October, 2011, 707 patients were admitted to JDJ for malaria with 67 deaths, giving a mortality 
rate of 0·0950. 1 year later, 811 patients were admitted with 48 deaths, giving a mortality rate of 0·059—a decrease risk 
of 0·6455 (95% CI 0·4514–0·9231, p=0·0155). In 2011, no patients received intravenous artesunate, 650 (92%) 
intramuscular artemether, and 21 (3%) intavenous quinine. 1 year later, 632 (78%) of malaria patients received 
intravenous artesunate and 178 (22%) intramuscular artemether.
Interpretation We show how malaria treatment can be changed quickly and eﬀ ectively towards contemporary care 
standards. Our ﬁ ndings support the probable beneﬁ t of intravenous artesunate in Liberia and the need for the 
Ministry of Health to ensure artesunate supply and provider friendly treatment guidelines.
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